Vir Biotechnology (VIR) AI Stock Analysis

• Market Cap: $805.53M
• Dividend Yield: N/A
• Average Volume (3M): 1.71M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.67
• Revenue Growth: -78.55%
• EPS Growth: 7.74%
• Country: US
• Employees: 408
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.17
• Shares Outstanding: 139,125,030
• 10 Day Avg. Volume: 1,011,440
• 30 Day Avg. Volume: 1,706,540
• PEG Ratio: 0.12
• Price to Book (P/B): 0.87
• Price to Sales (P/S): 13.48
• P/FCF Ratio: -2.20
• Enterprise Value/Market Cap: 0.48
• Enterprise Value/Revenue: 22.82
• Enterprise Value/Gross Profit: -0.88
• Enterprise Value/Ebitda: -0.75
• 1Y Price Target: $17.50
• Price Target Upside: 193.62% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7
• EPS Forecast (FY): -2.9
• Revenue Forecast (FY): $9.66M

• Rating: 48 Neutral
• Price Target: $6.00 ▲(0.67% Upside)

Vir Biotechnology's overall stock score is primarily impacted by its financial performance challenges, including declining revenues and profitability issues. While the technical analysis and recent corporate events provide some positive signals, the negative valuation metrics and ongoing financial losses weigh heavily on the score.

Positive Factors

Strategic Partnerships

The partnership with Norgine provides significant financial milestones and shared development costs, enhancing Vir's market position and financial stability.

Strong Cash Position

A strong cash position ensures operational flexibility and supports ongoing R&D efforts, crucial for long-term growth and stability.

Clinical Progress

Advancing clinical trials positions Vir for potential regulatory approvals, boosting future revenue streams and market competitiveness.

Negative Factors

Declining Revenue

Declining revenues indicate challenges in product sales and market penetration, which could hinder long-term financial performance and growth.

High R&D Expenses

High R&D costs strain financial resources and require successful outcomes to justify investments, impacting profitability if not managed well.

Continued Financial Losses

Ongoing financial losses highlight operational inefficiencies and the need for improved cost management to achieve sustainable profitability.

Vir Biotechnology Business Overview & Revenue Model

Company Description

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

How the Company Makes Money

Vir Biotechnology generates revenue primarily through the development and commercialization of its therapeutic products. Key revenue streams include sales of approved products, licensing agreements, and collaborations with pharmaceutical companies. The company has entered into significant partnerships, such as its collaboration with GlaxoSmithKline for the development of COVID-19 treatments, which can lead to milestone payments and royalties on future sales. Additionally, Vir may receive funding from government grants and contracts, especially during public health emergencies, contributing to its financial earnings.

Vir Biotechnology Financial Statement Overview

Summary

Vir Biotechnology is facing significant financial challenges, with negative net profit margins, declining revenue growth, and ongoing cash flow issues. The balance sheet shows low leverage but negative returns on equity, indicating financial instability.

Income Statement

Vir Biotechnology's income statement shows significant challenges with negative net profit margins and declining revenue growth. The TTM data reveals a gross profit margin of 95.53%, but this is overshadowed by a net loss, indicating inefficiencies in cost management. The revenue growth rate is negative, reflecting a downturn in sales performance. Overall, the company is struggling to maintain profitability.

Balance Sheet

The balance sheet indicates a relatively low debt-to-equity ratio of 0.10, suggesting conservative leverage. However, the return on equity is negative, highlighting the company's inability to generate positive returns for shareholders. The equity ratio is stable, but the overall financial health is compromised by persistent losses.

Cash Flow

The cash flow statement shows negative operating and free cash flows, with a slight decline in free cash flow growth. The operating cash flow to net income ratio is negative, indicating cash flow challenges. The free cash flow to net income ratio is slightly above 1, suggesting some alignment between cash flow and reported earnings, but overall cash flow management remains a concern.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	16.86M	74.20M	86.18M	1.62B	1.10B	67.25M
Gross Profit	-438.52M	-404.44M	-486.65M	994.83M	581.54M	67.25M
EBITDA	-511.54M	-508.91M	-641.64M	839.85M	426.56M	-291.54M
Net Income	-499.65M	-521.96M	-615.06M	515.84M	528.58M	-298.67M
Balance Sheet
Total Assets	1.02B	1.40B	1.92B	2.80B	1.95B	918.76M
Cash, Cash Equivalents and Short-Term Investments	506.51M	905.35M	1.52B	2.40B	708.14M	736.86M
Total Debt	100.17M	97.89M	124.54M	127.97M	137.49M	70.18M
Total Liabilities	223.35M	248.43M	328.82M	724.13M	522.42M	201.91M
Stockholders Equity	796.10M	1.15B	1.59B	2.08B	1.43B	716.85M
Cash Flow
Free Cash Flow	-460.43M	-453.65M	-800.36M	1.60B	-69.41M	-197.49M
Operating Cash Flow	-453.54M	-446.35M	-778.78M	1.66B	-47.59M	-190.94M
Investing Cash Flow	364.46M	499.37M	164.73M	-1.19B	-140.81M	-9.86M
Financing Cash Flow	4.01M	4.39M	7.38M	34.76M	100.33M	529.47M

Vir Biotechnology Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5.96
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VIR, the sentiment is Positive. The current price of 5.96 is below the 20-day moving average (MA) of 6.17, below the 50-day MA of 5.98, and above the 200-day MA of 5.53, indicating a neutral trend. The MACD of -0.04 indicates Positive momentum. The RSI at 52.31 is Neutral, neither overbought nor oversold. The STOCH value of 63.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VIR.

Vir Biotechnology Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AVXL	62 Neutral	$358.29M	-7.54	-43.11%	―	―	-5.71%
SEPN	61 Neutral	$1.14B	-17.49	-22.38%	―	2147.20%	-269.99%
XNCR	59 Neutral	$1.00B	-8.42	-19.61%	―	38.16%	48.43%
IOVA	54 Neutral	$1.01B	-2.30	-53.89%	―	175.62%	19.63%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VIR	48 Neutral	$805.53M	―	-49.06%	―	-78.55%	7.74%
IVA	46 Neutral	$874.10M	-1.25	―	―	-12.52%	-82.84%

Vir Biotechnology Corporate Events

Vir Biotechnology Secures Licensing Deal with Norgine

On December 16, 2025, Vir Biotechnology entered into a license agreement with Norgine Pharma UK Limited, granting Norgine exclusive commercial rights to a combination treatment for chronic hepatitis delta (CHD) in Europe, Australia, and New Zealand. Vir will receive an initial EUR 55 million reimbursement and up to EUR 495 million in milestones, with shared clinical development costs for ongoing trials. The combination treatment of tobevibart and elebsiran showed promising results in a Phase 2 trial, achieving significant virologic suppression and being well-tolerated, which could enhance Vir’s market positioning and impact stakeholders positively.

The most recent analyst rating on (VIR) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Vir Biotechnology stock, see the VIR Stock Forecast page.